Abstract
Several recent genome-wide studies showed that the genetic polymorphisms in the HLA-DQ region (rs9275572 and rs2856718) were related to chronic hepatitis B virus (HBV) infection and chronic hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC). We analyzed the two single-nucleotide polymorphisms for major HBV outcomes in Han Chinese. A total of 1291 samples were involved and peripheral blood samples were collected in this study. Matrix-assisted laser desorption/ionization time of flight mass spectrometry were used to genotype the single-nucleotide polymorphisms in the HLA-DQ region. Our study indicated the clear relationship between the HLA-DQ rs9275572 and HBV-related HCC after control for the effects of sex, drinking, and smoking. Health subjects with the HLA-DQ rs9275572 GA genotype would have a 0.641 (95 % CI 0.416, 0.985; P = 0.043) times lower odds of having HCC, and those with the AA genotype would have a 0.256 (95 % CI 0.106, 0.618; P = 0.002) times lower odds of having HCC, whereas the values of the other covariates were fixed. Whereas there was no significant difference found for the HLA-DQ rs2856718 AG and GG genotype. Our study suggested that HLA-DQ loci (rs9275572) were associated with HBV-related HCC as a protective factor in Han Chinese.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Ca-Cancer J clin. 2015;65:5–29.
McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15:223.
Yuen M, Hou J, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroen Hepatol. 2009;24:346–53.
World Health Organization. Hepatitis B. Fact sheet no 204. July 2014. Http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 9 Jan 2015, 2014,
Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J Gastroen Hepatol. 2011;26:221–7.
Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–29.
Yao M, Wang L, Dong Z, Qian Q, Shi Y, Yu D, et al. Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy. Tumor Biol. 2014;35:5857–68.
Xu J, Jia L, Ma H, Li Y, Ma Z, Zhao Y. Axl gene knockdown inhibits the metastasis properties of hepatocellular carcinoma via Pi3K/Akt-PAK1 signal pathway. Tumor Biol. 2014;35:3809–17.
Leung KC, Wong C, Zhu X, Lee S, Sham KWY, Lai JMY, et al. Ternary hybrid nanocomposites for gene delivery and magnetic resonance imaging of hepatocellular carcinoma cells. Quant Imaging Med Surg. 2013;3:302–7.
Yakaboski E, Jares A, Ma Y. Stem cell gene SALL4 in aggressive hepatocellular carcinoma: a cancer stem cell-specific target? Hepatol. 2014;60:419–21.
Luo H, Zhang H, Xin X, Huang W. Haplotype-based case-control study of DNA repair gene XRCC3 and hepatocellular carcinoma risk in a Chinese population. Tumor Biol. 2014;35:3415–9.
Zheng Y, Huang J, Zhan M, Zhao W, Liu B, He X, et al. Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma. Tumor Biol. 2014;35:11473–81.
Ye K, Chang S, Li J, Li X, Zhou Y, Wang Z. A functional and protein-protein interaction analysis of neuroepithelial cell transforming gene 1 in hepatocellular carcinoma. Tumor Biol. 2014;35:11219–27.
Lu Y, Wu Z, Peng Q, Ma L, Zhang X, Zhao J, et al. Role of IL-4 gene polymorphisms in HBV-related hepatocellular carcinoma in a Chinese population. PLoS One. 2014;9(10):e110061.
Chang H, Ahn SH, Kim DY, Shin J, Kim Y, Hong SP, et al. Association between CCR5 promoter polymorphisms and hepatitis B virus infection. The Korean journal of hepatology. 2005;11:116–24.
Zheng L, Li D, Wang F, Wu H, Li X, Fu J, et al. Association between hepatitis B viral burden in chronic infection and a functional single nucleotide polymorphism of the PDCD1 gene. J Clin Immunol. 2010;30:855–60.
Thio CL, Mosbruger TL, Kaslow RA, Karp CL, Strathdee SA, Vlahov D, et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol. 2004;78:11258–62.
Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-drb1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepatitis. 2007;14:841–8.
Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003;98:144–50.
Zheng MH, Xiao DD, Lin XF, Wu SJ, Peng MM, Yu XY, et al. The tumour necrosis factor-alpha-238a allele increases the risk of chronic HBV infection in european populations. J Viral Hepatitis. 2012;19:E11–7.
Deng G, Zhou G, Zhai Y, Li S, Li X, Li Y, et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatol. 2004;40:318–26.
Deng G, Zhou G, Zhang R. Regulatory polymorphisms in the promoter of CXCl10 gene and disease progression in male hepatitis B virus carriers (vol 134, pg 716, 2008). Gastroenterology. 2008;135:713.
Kim YJ, Kim HY, Kim JS, Lee JH, Yoon JH, Kim CY, et al. Putative association of transforming growth factor-alpha polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Viral Hepatitis. 2010;17:518–26.
Godkin A, Davenport M, Hill A. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine non responsiveness. Hepatol. 2005;41:1383–90.
Zhang X, Jia J, Dong J, Yu F, Ma N, Li M, et al. HLA-DQ polymorphisms with HBV infection: different outcomes upon infection and prognosis to lamivudine therapy. J Viral Hepatitis. 2014;21:491–8.
Al-Qahtani AA, Al-Anazi MR, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, et al. Association between HLA variations and chronic hepatitis B virus infection in Saudi Arabian patients. PLoS One. 2014;9(1):e80445.
Mbarek H, Ochi H, Urabe Y, Kumar V, Kubo M, Hosono N, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet. 2011;20:3884–92.
Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011;43:455.
Kwak MS, Choi JW, Lee JS, Kim KA, Suh JH, Cho YS, et al. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir. J Viral Hepatitis. 2011;18:E432–8.
Rapti I, Dimon E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatol. 2007;45:307–13.
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatol. 2005;42:1208–36.
El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.
Jiang D, Sun J, Cao G, Liu Y, Lin D, Gao Y, et al. Genetic variants in stat4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013;45:72–105.
Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, et al. Genome-wide association study confirming association of HLA-DQ with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One. 2012;7(6):e39175.
Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev. 2009;22:370.
Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroentero. 2007;13:1770–87.
Acknowledgments
We thank the Postgraduate Innovation Project of Hebei Department of Education Office of Academic Degrees, Foundation of Health Commission of Hebei (20090048), and Hebei medical scientific research key project (20150626) who supported this study, and all the staffs who were involved in the subject recruitment, telephone interviews, sample preparation, and laboratory assays are thanked for their hard work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Informed consent was obtained from each subject. The study protocol conformed to the 1975 Declaration of Helsinki and was approved by the ethics committee of Hebei Medical University (No.2016009).
Conflicts of interest
None
Additional information
Xia Gao and Wenxuan Liu contributed equally to this work.
Rights and permissions
About this article
Cite this article
Gao, X., Liu, W., Zhang, X. et al. Genetic polymorphism of HLA-DQ confers susceptibility to hepatitis B virus-related hepatocellular carcinoma: a case-control study in Han population in China. Tumor Biol. 37, 12103–12111 (2016). https://doi.org/10.1007/s13277-016-5077-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-016-5077-z